These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23671618)

  • 1. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data.
    Ahmad Kiadaliri A; Gerdtham UG; Nilsson P; Eliasson B; Gudbjörnsdottir S; Carlsson KS
    PLoS One; 2013; 8(5):e62650. PubMed ID: 23671618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden.
    Ringborg A; Yin DD; Martinell M; Stålhammar J; Lindgren P
    Eur J Cardiovasc Prev Rehabil; 2009 Oct; 16(5):576-82. PubMed ID: 19491686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.
    Laxy M; Schöning VM; Kurz C; Holle R; Peters A; Meisinger C; Rathmann W; Mühlenbruch K; Kähm K
    Pharmacoeconomics; 2019 Dec; 37(12):1485-1494. PubMed ID: 31350720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.
    McEwan P; Bennett H; Ward T; Bergenheim K
    Pharmacoeconomics; 2015 Feb; 33(2):149-61. PubMed ID: 25344660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
    Nguyen C; Luthra R; Kuti E; Willey VJ
    Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials.
    Basu S; Sussman JB; Berkowitz SA; Hayward RA; Yudkin JS
    Lancet Diabetes Endocrinol; 2017 Oct; 5(10):788-798. PubMed ID: 28803840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study.
    Adamsson Eryd S; Gudbjörnsdottir S; Manhem K; Rosengren A; Svensson AM; Miftaraj M; Franzén S; Björck S
    BMJ; 2016 Aug; 354():i4070. PubMed ID: 27492939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population.
    Kern DM; Mellström C; Hunt PR; Tunceli O; Wu B; Westergaard M; Hammar N
    Curr Med Res Opin; 2016; 32(4):703-11. PubMed ID: 26709864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting mortality in people with type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data.
    Kelly PJ; Clarke PM; Hayes AJ; Gerdtham UG; Cederholm J; Nilsson P; Eliasson B; Gudbjornsdottir S
    Diabet Med; 2014 Aug; 31(8):954-62. PubMed ID: 24750341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischemic stroke rates decrease with increased ticagrelor use after acute myocardial infarction in patients treated with percutaneous coronary intervention.
    Ulvenstam A; Henriksson R; Söderström L; Mooe T
    Eur J Prev Cardiol; 2018 Jul; 25(11):1219-1230. PubMed ID: 29929389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register.
    Zethelius B; Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K; Cederholm J;
    Eur J Prev Cardiol; 2014 Feb; 21(2):244-51. PubMed ID: 24227183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.
    Kohli P; Steg PG; Cannon CP; Smith SC; Eagle KA; Ohman EM; Alberts MJ; Hoffman E; Guo J; Simon T; Sorbets E; Goto S; Bhatt DL;
    Am J Med; 2014 Jan; 127(1):53-60.e1. PubMed ID: 24280110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of radial pulse spectrum on the risk of major adverse cardiovascular events in patients with type 2 diabetes.
    Chang CW; Liao KM; Chang YT; Wang SH; Chen YC; Wang GC
    J Diabetes Complications; 2019 Feb; 33(2):160-164. PubMed ID: 30381150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
    Svanström H; Ueda P; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
    Lancet Diabetes Endocrinol; 2019 Feb; 7(2):106-114. PubMed ID: 30527909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of prediction models for cardiovascular and mortality risk in people with type 2 diabetes: An external validation in 23 685 adults included in the UK Biobank.
    Zhang Y; Jiong OX; Tang S; Tang YC; Wong CT; Ng CS; Quan J
    Diabetes Obes Metab; 2024 May; 26(5):1697-1705. PubMed ID: 38297974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
    Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
    Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
    Ou HT; Chang KC; Li CY; Wu JS
    Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review.
    Brennan VK; Mauskopf J; Colosia AD; Copley-Merriman C; Hass B; Palencia R
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):111-23. PubMed ID: 25555462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular diastolic function, assessed by echocardiography and tissue Doppler imaging, is a strong predictor of cardiovascular events, superior to global left ventricular longitudinal strain, in patients with type 2 diabetes.
    Blomstrand P; Engvall M; Festin K; Lindström T; Länne T; Maret E; Nyström FH; Maret-Ouda J; Östgren CJ; Engvall J
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):1000-7. PubMed ID: 25750201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
    Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
    BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.